Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway
Authors:
- 19 November 2010
- journal article
- research article
- Published by Wiley in Phytotherapy Research
- Vol. 25 (6) , 833-837
Abstract
Inactivation of epidermal growth factor receptor (EGFR) is a prime method used in colon cancer therapy. Here it is shown that chrysophanic acid, a natural anthraquinone, has anticancer activity in EGFR‐overexpressing SNU‐C5 human colon cancer cells. Chrysophanic acid preferentially blocked proliferation in SNU‐C5 cells but not in other cell lines (HT7, HT29, KM12C, SW480, HCT116 and SNU‐C4) with low levels of EGFR expression. Chrysophanic acid treatment in SNU‐C5 cells inhibited EGF‐induced phosphorylation of EGFR and suppressed activation of downstream signaling molecules, such as AKT, extracellular signal‐regulated kinase (ERK) and the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K). Chrysophanic acid (80 and 120 µm) significantly blocked cell proliferation when combined with the mTOR inhibitor, rapamycin. These findings offer the first evidence of anticancer activity for chrysophanic acid via EGFR/mTOR mediated signaling transduction pathway. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 28 references indexed in Scilit:
- Anti‐proliferative effect of rhein, an anthraquinone isolated from Cassia species, on Caco‐2 human adenocarcinoma cellsJournal of Cellular and Molecular Medicine, 2010
- EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumorsLaboratory Investigation, 2009
- Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc Δ716 miceProceedings of the National Academy of Sciences, 2008
- Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane ModelClinical Cancer Research, 2008
- Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugsBritish Journal of Cancer, 2008
- The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer TherapyClinical Cancer Research, 2007
- Anthraquinones, Cdc25B phosphatase inhibitors, isolated from the roots ofPolygonum multiflorumThunb.Natural Product Research, 2007
- Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumorsMolecular Cancer Therapeutics, 2006
- The tor pathway: a target for cancer therapyNature Reviews Cancer, 2004
- The Role of Individual SH2 Domains in Mediating Association of Phospholipase C-γ1 with the Activated EGF ReceptorJournal of Biological Chemistry, 1999